Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6818857 | Psychoneuroendocrinology | 2015 | 11 Pages |
Abstract
People with schizophrenia per se may not have levels of adiponectin lower than controls, though treatment with SGAs is associated with this metabolic abnormality. This bears clinical significance because of hypoadiponectinemia involvement in cardiovascular diseases, even if mechanisms whereby SGAs affect adiponectin remain unexplained. Longitudinal studies evaluating long-term effects of SGAs on adiponectin are needed.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Francesco Bartoli, Annamaria Lax, Cristina Crocamo, Massimo Clerici, Giuseppe Carrà ,